Posted by Michael Wonder on 08 Nov 2020
Midostaurin for treating advanced systemic mastocytosis
6 November 2020 - The Department of Health and Social Care has asked NICE to produce guidance on using midostaurin in the NHS in England.
Midostaurin is not recommended, within its marketing authorisation, for treating advanced systemic mastocytosis (aggressive systemic mastocytosis, systemic mastocytosis with associated haematological neoplasms and mast cell leukaemia) in adults.
Evidence suggests that midostaurin is more effective than current treatments, but the evidence is uncertain.
